Array trial shows positive drug results
BOULDER – Array BioPharma Inc. released results of a phase 1 trial for its drug ARRY-797, designed to help treat cancer patients and others with sub-chronic pain.
Boulder-based Array’s ARRY-797, a p38 inhibitor, showed positive results in a seven-day dose escalation trial with healthy volunteers. It also evaluated rheumatoid arthritis patients taking methotrexate in a 28-day trail.
Both trials showed the drug was well tolerated, inhibited inflammation, reduced bone remodeling, and allowed patients to better assess pain.
“Since these results are similar to other p38 inhibitors evaluated in rheumatoid arthritis, these findings have led us to discontinue testing of ARRY-797 in chronic inflammatory diseases,” Kevin Koch, Array’s president and chief scientific officer, said in a statement.
BOULDER – Array BioPharma Inc. released results of a phase 1 trial for its drug ARRY-797, designed to help treat cancer patients and others with sub-chronic pain.
Boulder-based Array’s ARRY-797, a p38 inhibitor, showed positive results in a seven-day dose escalation trial with healthy volunteers. It also evaluated rheumatoid arthritis patients taking methotrexate in a 28-day trail.
Both trials showed the drug was well tolerated, inhibited inflammation, reduced bone remodeling, and allowed patients to better assess pain.
“Since these results are similar to other p38 inhibitors evaluated in rheumatoid arthritis, these findings have led us to discontinue testing of ARRY-797 in chronic inflammatory…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!